A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1660-1670

  Furman, Wayne L ^a,b   McGregor, Lisa M ^a,b   McCarville, M Beth ^a   Onciu, Mihaela ^a,d   Davidoff, Andrew M ^a,b   Kovach, Sandy ^a   Hawkins, Dana ^a   McPherson, Valerie ^a   Houghton, Peter J ^c   Billups, Catherine A ^a   Wu, Jianrong ^a   Stewart, Clinton F ^a,b   Santana, Victor M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d OncoMetrix   (United States)

Author keywords

ATP binding cassette transporters; Clinical trial; Gefitinib; Irinotecan; Neuroblastoma; Phase II

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOFOS; ETOPOSIDE; FIRTECAN; GEFITINIB; IRINOTECAN; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; TOPOTECAN;

ABDOMINAL PAIN; ADRENAL TUMOR; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BONE MARROW TUMOR; CANCER SURGERY; CAUCASIAN; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MYCN GENE; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT RESPONSE; TUMOR GENE; TUMOR VOLUME; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; HOMOVANILLIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; L-LACTATE DEHYDROGENASE; MALE; NEOPLASM PROTEINS; NEUROBLASTOMA; PILOT PROJECTS; QUINAZOLINES; RISK FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; VANILMANDELIC ACID;

EID: 84866734693     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9724-3     Document Type: Article

References (61)

1. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36(5):393-403
2. Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB (1996) Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 14(1):37-47
3. Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3(3):423-431
4. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17(6):1815-1824
5. Klein S, Levitzki A (2007) Targeted cancer therapy: promise and reality. Adv Cancer Res 97:295-319. doi:10.1016/S0065-230X (06)97013-4
6. Sawyers C (2004) Targeted cancer therapy. Nature 432 (7015):294-297. doi:10.1038/nature03095
7. Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9(5):363-366. doi:10.1038/nrd3181
8. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64(20):7491-7499
9. Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, Rubin EH (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63(12):3228-3233
10. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y (2004) Gefitinib reverses breast cancer resistance proteinmediated drug resistance. Mol Cancer Ther 3(9):1119-1125
11. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65(6):1485-1495
12. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD, Haber M (2005) Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 4 (4):547-553. doi:10.1158/1535-7163.MCT-04-0161
13. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH (2001) The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10- hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61(2):739-748
14. Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M, Tsuchiya K, Iehara T, Gotoh T, Sugimoto T (2007) Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 358(1):226-232. doi:10.1016/j. bbrc.2007.04.124
15. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65(21):9868-9875. doi:10.1158/0008-5472.CAN-04-2426
16. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 7(5):1204-1213
17. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research 8(5):994-1003
18. Ciardiello F, Bianco R, Damiano V, De LS, Pepe S, De PS, Fan Z, Mendelsohn J, Bianco AR, Tortora G (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5 (4):909-916
19. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201-1208
20. Baselga J (2001) Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 19(18 Suppl):41S-44S
21. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
22. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73(2):405-416
23. Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF (2009) Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27(27):4599-4604. doi:10.1200/JCO.2008.19.6642
24. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NK (2001) Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 19(11):2821-2828
25. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF (2004) Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 22(5):829-837
26. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De BB, Evans AE, Favrot M, Hedborg F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466-1477
27. Owens TS, Dodds H, Fricke K, Hanna SK, Crews KR (2003) High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 788 (1):65-74
28. Beal S, Sheiner LB (1998) NONMEM users guide.(Part I-VIII). NONMEM. University of California at San Francisco, San Francisco
29. Tan M, Xiong X (1996) Continuous and group sequential conditional probability ratio tests for phase II clinical trials. Stat Med 15(19):2037-2051
30. Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8 (4):313-322
31. Komuro H, Li P, Tsuchida Y, Yokomori K, Nakajima K, Aoyama T, Kaneko M, Kaneda N (1994) Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xenotransplanted neuroblastoma. Med Pediatr Oncol 23(6):487-492
32. Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, Gyergyay F, Benard J, Morizet J, Boland I, Ardouin P, Bressacde-Paillerets B, Gouyette A (1996) Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74(4):537-545
33. Rossler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, Niemeyer CM, Vassal G (2009) EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res 29 (4):1327-1333
34. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 25(29):4622-4627. doi:10.1200/JCO.2007.11.6103
35. Vassal G, Giammarile F, Brooks M, Geoerger B, Couanet D, Michon J, Stockdale E, Schell M, Geoffray A, Gentet JC, Pichon F, Rubie H, Cisar L, Assadourian S, Morland B (2008) A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 44 (16):2453-2460. doi:10.1016/j.ejca.2008. 08.003
36. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC (2005) Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23(25):6172-6180. doi:10.1200/JCO.2005.11.429
37. Chau I, CunninghamD, Hickish T, Massey A, Higgins L, Osborne R, Botwood N, Swaisland A (2007) Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol 18(4):730-737. doi:10.1093/annonc/mdl481
38. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M (1996) Expression of the gene for multidrug-resistanceassociated protein and outcome in patients with neuroblastoma. N Engl J Med 334(4):231-238
39. Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, Seeger RC, Reynolds CP (2000) Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med Pediatr Oncol 35 (6):619-622
40. Pajic M, Norris MD, Cohn SL, Haber M (2005) The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome. Cancer Lett 228(1-2):241-246
41. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, Norris MD (2006) Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24(10):1546-1553
42. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD (1997) The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 33 (12):2031-2036
43. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101(39):14228-14233
44. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90(7):505-511
45. Layfield LJ, Thompson JK, Dodge RK, Kerns BJ (1995) Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr-a survival study. J Surg Oncol 59(1):21-27
46. Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, Furth ME, Biedler JL (1988) Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 38(2):87-97
47. Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M, Tsuchiya K, Iehara T, Gotoh T, Sugimoto T (2007) Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 358(1):226-232
48. Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J Jr (2008) Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res 14(20):6531-6537
49. Vickers AJ, Ballen V, Scher HI (2007) Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res 13 (3):972-976
50. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R (2004) Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase ii investigational window: a Pediatric Oncology Group Study. J Clin Oncol 22(20):4119-4126
51. Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA (1994) Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol 12(8):1616-1620
52. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324-1334. doi:10.1056/NEJMoa0911123
53. Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT (2005) Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11(4):1504-1511. doi:10.1158/1078-0432.CCR-04-1758
54. Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonneterre ME, Beijnen JH, Schellens JH, Bonneterre J (2006) Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 12(12):3774-3781. doi:10.1158/1078-0432. CCR-05-2368
55. Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C (2006) A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 58(2):165-172. doi:10.1007/s00280-005-0138-9
56. Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM (2006) Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24(4):563-570. doi:10.1200/JCO.2005.03.2847
57. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ 3rd, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64(20):7491-7499. doi:10.1158/0008-5472.CAN-04-0096
58. Donfrancesco A, De Ioris MA, McDowell HP, De Pasquale MD, Ilari I, Jenkner A, Castellano A, Cialfi S, De Laurentis C, Dominici C (2010) Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Pediatr Blood Cancer 54 (1):55-61. doi:10.1002/pbc.22219
59. Donfrancesco A, Jenkner A, De Ioris MA, Ilari I, Castellano A, De Laurentis C, Garganese MC, Milano GM, Dominici C (2007) Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report. J Pediatr Hematol Oncol 29(11):799-803. doi:10.1097/MPH.0b013e31815815f6
60. Qayed M, Powell C, Morgan ER, Haugen M, Katzenstein HM (2010) Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 54(5):761-763. doi:10.1002/pbc.22408
61. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK (2009) Phase I trial of oral irinotecan and temozolomide for children with relapsed highrisk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol 27(8):1290-1296. doi:10.1200/JCO.2008.18.5918